Annual revenue rose from KRW 793 billion in 2022 to KRW 804 billion in 2023 (up 1.4% year on year), then fell to KRW 779.8 billion in 2024 (down 3.0%) and KRW 657.6 billion in 2025 (down 15.7%), a two-year decline from 2024 through 2025. Among 2022 to 2025, 2023 was the largest year and 2025 the smallest.
Operating results moved from an operating loss of KRW 7.55 billion in 2022 to operating profit of KRW 20.8 billion in 2023 (a turn to profit), an operating loss of KRW 11.6 billion in 2024 (a turn to loss), and operating profit of KRW 38.7 billion in 2025 (a turn to profit).
Operating margins were -1.0%, 2.6%, -1.5% and 5.9%.
Net income attributable to controlling shareholders was a loss of KRW 83.1 billion in 2022, a loss of KRW 13.2 billion in 2023 (losses continued but narrowed), a loss of KRW 66.4 billion in 2024 (losses continued and widened), and income of KRW 14.6 billion in 2025 (a turn to profit).
The 2025 net income of KRW 34.6 billion differs from the controlling-shareholder figure because it includes non-controlling interests. The company said 2024 carried a one-time cost from impairment of a subsidiary, while 2025 had no such impairment factor, which improved results.
The recovery was led by better profitability and streamlined operations at Jeil Pharmaceutical, with a higher share of own products and a lower cost ratio. The debt ratio fell from 106.2% in 2022 to 118.8% in 2023, 103.6% in 2024 and 86.9% in 2025.
At the end of 2025, total equity was KRW 469.1 billion, of which KRW 318.7 billion belonged to controlling shareholders, and total liabilities were KRW 407.5 billion. Operating cash flow went from -KRW 20.8 billion in 2022 and -KRW 4.42 billion in 2023 to KRW 4.54 billion in 2024 and KRW 390 million in 2025.
Quarterly, operating profit fell from KRW 18.1 billion in Q3 2025 to KRW 6.55 billion in Q4 2025 (down 63.8% from the prior quarter) and KRW 3.56 billion in Q1 2026 (down 45.7%). Q2 2026 revenue rose 9.5% quarter on quarter to KRW 164.7 billion, yet the company posted an operating loss of KRW 9.94 billion.
Q3 2026 revenue was KRW 156.7 billion (down 2.9% year on year) with an operating loss of KRW 3.4 billion. Net income attributable to controlling shareholders over the last four quarters totals KRW 2.53 billion.